PMS Support + Hormone Balance
Originaltext auf Französisch.
In Kanada zugelassenes natürliches Gesundheitsprodukt
Falls dieses Produkt in Frankreich verkauft würde
- Dose déclarée au-delà d'une limite
Zinc: bis zu 25 mg täglich gemäß der von Health Canada veröffentlichten Dosierung (2 unités posologiques par jour au plus, pour les adultes), über der französischen Höchstdosis von 15 mg für ein Nahrungsergänzungsmittel (Erlass von 2006, seit November 2006 nicht überarbeitet).
arrêté du 9 mai 2006, annexe III. Französische Verordnungen vom 9. Mai 2006 und 14. November 2006 wie im Amtsblatt veröffentlicht (Tageshöchstdosen), abgerufen am 21. Oktober 2026.
Eine Tagesmenge wird nur bei ausdrücklicher oraler Dosierung für Erwachsene berechnet, die pro Tag und in einer zur Produktform passenden festen Einheit angegeben ist. Mehrdeutige Einheiten, Flüssigkeiten, Pulver und pädiatrische Dosen werden nicht hochgerechnet. Eine nicht berechnete Menge wird nicht mit Dosisgrenzwerten verglichen. Diese Analyse stellt weder eine Verkaufszulassung in Frankreich noch eine Sicherheits- oder Wirksamkeitsbewertung dar.
Zusammensetzung
| Arzneilicher Inhaltsstoff und Quelle | Je Dosiseinheit laut Quelle | Täglich höchstens, Erwachsene |
|---|---|---|
| Vitamine B12 Quelle : Méthylcobalamine | 50 microgram | 100 µg |
| Folate Quelle : L-5-methyltetrahydrofolate | 200 microgram | Nicht berechnet |
| Paeonia lactiflora Quelle : Racine Extrakt : Matériel brut sec Extraktionsverhältnis : 4:1 Trockenpflanzenäquivalent : 160 mg | 40 mg | Nicht berechnet |
| Withania somnifera Quelle : Racine Extrakt : Matériel brut sec Extraktionsverhältnis : 5:1 Trockenpflanzenäquivalent : 150 mg | 30 mg | Nicht berechnet |
| Zinc Quelle : Citrate de zinc | 12,5 mg | 25.000 µg |
| Hypericum perforatum Quelle : Sommité | 80 mg | Nicht berechnet |
| Zingiber officinale Quelle : Rhizome Extrakt : Matériel brut sec Extraktionsverhältnis : 4:1 Trockenpflanzenäquivalent : 80 mg | 20 mg | Nicht berechnet |
Nicht arzneiliche Inhaltsstoffe
Propylène glycol, Dioxyde de silicium, Stéarate de magnésium, Cellulose microcristalline
In Kanada empfohlene Dosen
| Bevölkerungsgruppe | Alter | Menge pro Einnahme | Häufigkeit |
|---|---|---|---|
| Adultes | minimum : 19 ans | 1 Comprimé | 2 Tous les jours |
In Kanada zugelassene Verwendungen
Calcium intake, when combined with sufficient vitamin D, a healthy diet, and regular exercise, may reduce the risk of developing osteoporosis. Helps (to) maintain/support immune function/system. Helps in energy metabolism and tissue formation. Helps in the development and maintenance of bones and teeth. Helps to form red blood cells. Helps to maintain healthy bones, hair, nail and/or skin. Helps to maintain normal blood glucose levels. Provides support for healthy glucose metabolism. Helps reduce the severity and duration of symptoms associated with recurrent breast pain (cyclical mastalgia). Helps to support/promote healthy estrogen metabolism/balance. Source of /Provides antioxidants that help fight/protect (cell) against/reduce (the oxidative effects of/the oxidative damage caused by/cell damage caused by) free radicals. Chaste tree is used in Herbal Medicine (as a hormone normaliser) to help stabilise menstrual cycle irregularities and relieve premenstrual symptoms. Chaste Tree is used in Herbal Medicine to help relieve symptoms associated with menopause, such as hot flushes.
Originaltext auf Englisch.
Eine in Kanada zugelassene Verwendung ist keine in der Europäischen Union zugelassene gesundheitsbezogene Angabe. Beachten Sie das Register gesundheitsbezogener Angaben.
Warnhinweise in Kanada
Known Adverse Reactions : Some people may experience mild gastrointestinal disturbances, nausea, restlessness and/or headaches . Stop use if hypersensitivity/allergy occurs. Stop use and consult a health care practitioner/health care provider/health care professional/ doctor/physician if you experience breast pain, discomfort and/or tenderness. Some people may experience drowsiness. Exercise caution if operating heavy machinery, driving a motor vehicle or involved in activities requiring mental alertness.
Originaltext auf Englisch.
Cautions and Warnings : Consult a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen. Avoid prolonged exposure to sunlight, ultraviolet light (UV) or UV therapy. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are taking antianxiety or seizure medications, antihistamines, bronchodilators, muscle relaxants and/or opiates. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are taking medications for diabetes, high blood pressure or seizures. Stop use and consult a health care practitioner/health care provider/health care professional/doctor/physician if menstruation is delayed or absent, or if you experience increased menstrual bleeding time. Avoid taking with alcohol or products that cause drowsiness. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are attempting to conceive. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are taking medications or natural health products. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you have a liver disorder or symptoms of low estrogen (such as joint pain, mood changes, changes in libido, hot flashes, night sweats, vaginal dryness or irregular menstruations). Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use to exclude the diagnosis of a serious cause of hormonal imbalance. Stop use and consult a health care practitioner/health care provider/health care professional/doctor/physician if you develop liver-related symptoms (e.g. yellowing of the eyes and/or skin, dark urine, abdominal pain, jaundice) or symptoms of low estrogen. Consult a health care practitioner/health care provider/health care professional/doctor/ physician prior to use if you are taking hormone-containing medications such as progesterone preparations or hormone replacement therapy.
Originaltext auf Englisch.
Produktdaten
- Inhaber
- Vitaminme Canada Inc.
- NPN oder DIN-HM
- 80118438
- Status
- Aktive Lizenz
- Lizenzdatum
- 6. Mai 2022
- Überarbeitungsdatum
- 20. August 2024
- Form
- Comprimé
- Verabreichungsweg
- Orale
- Art des Antrags
- Générale (non traditionelle)
Quelle
Amtlicher Health-Canada-Eintrag, Zulassung 80118438
Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise, abgerufen am 27. Oktober 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Originaltext auf Englisch.
Originaltext auf Französisch.
Die unter demselben Namen in Europa verkaufte Rezeptur kann abweichen. Diese Angaben ersetzen keinen ärztlichen oder pharmazeutischen Rat.
Offizielle Warnhinweise (Health Canada)
Health Canada veröffentlicht Warnhinweise zu diesen Zutaten:
- Withania somnifera
Warnhinweis, Geltungsbedingung und zitierte Studien lesen
Offizieller Originaltext auf Englisch.
ASHWAGANDHA - WITHANIA SOMNIFERA
Art der Anwendung: Oral
Vorsichtsmaßnahmen und Warnhinweise
Anwendungsbedingung: General debility; Memory enhancement; Adaptogen; Restlessness/nervousness.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Anwendungsbedingung: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Upton 2000; McGuffin et al. 1997).
Von Health Canada zitierte Quellen (3)
- McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press, LLC; 1997.
- Upton R, editor. American Herbal Pharmacopoeia and Therapeutic Compendium: Ashwagandha Root (Withania somnifera) - Standards of Analysis, Quality Control, and Therapeutics. Santa Cruz (CA): American Herbal Pharmacopoeia; 2000.
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze K, éditeurs. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13e édition. Washington (DC) : American Pharmaceutical Association; 2002.
When using this product exercise caution if you drive or use machinery as you may experience drowsiness (Berardi et al. 2002).
Von Health Canada zitierte Quellen (3)
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA and Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
- McGuffin M, Hobbs C, Upton R, Goldberg A, éditeurs. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL) : CRC Press, LLC; 1997.
- Upton R, éditeur. Ashwagandha Root, Withania somnifera Analytical, Quality Control, And Therapeutic Monograph. Santa Cruz (CA) : American Herbal Pharmacopoeia and Therapeutic Compendium; 2000.
- Hypericum perforatum
Warnhinweis, Geltungsbedingung und zitierte Studien lesen
Offizieller Originaltext auf Englisch.
ST. JOHN'S WORT -HYPERICUM PERFORATUM- Oral
Vorsichtsmaßnahmen und Warnhinweise
Anwendungsbedingung: Healthy mood balance.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a psychological disorder such as anxiety or depression.
Anwendungsbedingung: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Brinker 2010; Barnes et al. 2007; Mills and Bone 2005).
Von Health Canada zitierte Quellen (3)
- Barnes J, Anderson LA, Philipson JD. 2007. Herbal Medicines, 3rd edition. London (GB): The Pharmaceutical Press.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications. 2010.
- Mills S, Bone K. 2005. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking seizure medications, antihistamines, bronchodilators, muscle relaxants and/or opiates (Brinker 2010; Barnes et al. 2007; Mills and Bone 2005; Kawaguchi et al. 2004; Morimoto et al. 2004; Eich-Höchli et al. 2003; Dresser et al. 2003; Hoffman 2003; Markowitz et al. 2003; Xie et al. 2003; Dannawi 2002; Gurley et al. 2002; Spinella and Eaton 2002; Wang et al. 2002; Parker et al. 2001; Wang et al. 2001; Burstein et al. 2000; Nebel et al. 1999).
Von Health Canada zitierte Quellen (17)
- Barnes J, Anderson LA, Philipson JD. 2007. Herbal Medicines, 3rd edition. London (GB): The Pharmaceutical Press.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications. 2010.
- Burstein AH, Horton RL, Dunn T, Alfaro RM, Piscitelli SC, Theodore W. 2000. Lack of effect of St John's Wort on carbazepine pharmacokinetics in healthy volunteers. Clinical Pharmacology and Therapeutics 68(6):605-612.
- Dannawi M. 2002. Possible serotonin syndrome after combination of buspirone and St John's wort. Journal of Psychopharmacology 16(4):401.
- Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. 2003. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clinical Pharmacology and Therapeutics 73(1):41-50.
- Eich-Höchli D, Oppliger R, Golay KP, Baumann P, Eap CB. 2003. Methadone maintenance treatment and St John's wort: a case report. Pharmacopsychiatry 36(1):35-37.
- Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY. 2002. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clinical Pharmacology and Therapeutics 72(3):276-287.
- Kawaguchi A, Ohmori M, Tsuruoka S, Nishiki K, Harada K, Miyamori I, Yano R, Nakamura T, Masada M, Fujimura A. 2004. Drug interaction between St John's Wort and quazepam. British Journal of Clinical Pharmacology 58(4):403-410.
- Markowitz JS, Donovan JL, DeVane CL, Talor RM, Ruan Y, Wang J, Chavin KD. 2003. Effect of St. John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. The Journal of the American Medical Association. 290(11):1500-1504.
- Mills S, Bone K. 2005. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone.
- Morimoto T, Kotegawa T, Tsutsumi K, Ohtani Y, Imai H, Nakano S. 2004. Effect of St. John's wort on the pharmacokinetics of theophylline in healthy volunteers. Journal of Clinical Pharmacology 44(1):95-101.
- Nebel A, Schneider BJ, Baker RK, Kroll DJ. 1999. Potential metabolic interaction between St. John's wort and theophylline. The Annals of Pharmacotherapy 33(4):502.
- Parker V, Wong AH, Boon HS, Seeman MV. 2001. Adverse reactions to St John's wort. Canadian Journal of Psychiatry 46(1):77-79.
- Spinella M, Eaton LA. 2002. Hypomania induced by herbal and pharmaceutical psychotropic medicines following mild traumatic brain injury. Brain Injury 16(4):359-367.
- Wang ZQ, Hamman MA, Huang SM, Lesko LJ, Hall SD. 2002. Effect of St John's wort on the pharmacokinetics of fexofenadine. Clinical Pharmacology and Therapeutics 71(6):414-420.
- Wang ZQ, Gorski C, Hamman MA, Huang S, Lesko LJ, Hall SD. 2001. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clinical Pharmacology and Therapeutics 70(4):317-326.
- Xie R, Tan L, Polasek EC, Hong C, Teillol-Foo M, Gordi T, Sharma A, Nickens DJ, Arakawa T, Knuth DW, Antal EJ. 2003. CYP3A and P-glycoprotein induction with St. John's wort in healthy volunteers of selected ethnic populations. Journal of Clinical Pharmacology 45(3):352-356.
1 im Text zitierte Studie hat keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).
When using this product avoid prolonged exposure to sunlight, ultraviolet light (UV) or UV therapy (Brinker 2010; Barnes et al. 2007; Mills and Bone 2005; ESCOP 2003; Hoffmann 2003; McGuffin et al. 1997).
Von Health Canada zitierte Quellen (6)
- Barnes J, Anderson LA, Philipson JD. 2007. Herbal Medicines, 3rd edition. London (GB): The Pharmaceutical Press.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications. 2010.
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
- Hoffmann D. 2003. Medical Herbalism: The Science and Practice of Herbal Medicine. Rochester (VT): Healing Arts Press.
- McGuffin M, Hobbs C, Upton R, Goldberg A, editors. 1997. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press.
- Mills S, Bone K. 2005. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone.
When using this product exercise caution if you drive or use machinery as you may experience drowsiness (Bilia et al. 2002; Ernst et al. 1998).
Von Health Canada zitierte Quellen (2)
- Bilia AR, Gallori S, Vincieri FF. St John's wort and depression: efficacy, safety and tolerability - an update. Life Sciences 2002;70(26):3077-3096. PubMed Übersichtsartikel
- Ernst E, Rand JI, Barnes J, Stevinson C. Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.). European Journal of Clinical Pharmacology 1998;54:589-594. PubMed Systematische Übersicht
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Gegenanzeigen
Do not use if you are taking antidepressants, anxiolytics, anti-cancer, cardiovascular, contraceptive medications, blood thinners, anti-HIV agents and/or medications to suppress the immune system (Brinker 2010; Barnes et al. 2007; Bradley 2006; Mills and Bone 2005; Murphy et al. 2005; Frye et al. 2004; Hebert et al. 2004; Jiang et al. 2004; Mueller et al. 2004; Smith et al. 2004; Sparreboom et al. 2004; Tannergren et al. 2004; Wichtl 2004; Alscher and Klotz 2003; Bauer et al. 2003; Dresser et al. 2003; ESCOP 2003; Hall et al. 2003; Hoffmann 2003; Pfrunder et al. 2003; Schwarz et al. 2003; Bolley 2002; Gorski et al. 2002; Mathijssen et al. 2002; Ahmed et al. 2001; De Maat et al. 2001; Moschella and Jaber 2001; Roby et al. 2001; Sugimoto et al. 2001; Turton-Weeks 2001; Wang et al. 2001; Barone et al. 2000; Durr et al. 2000; Karliova et al. 2000; Mai et al. 2000; Piscitelli et al. 2000; Ruschitzka et al. 2000; Ernst 1999; Johne et al. 1999; Maurer et al. 1999; Rey and Walter 1998).
Von Health Canada zitierte Quellen (41)
- Ahmed SM, Banner NR, Dubrey SW. 2001. Low cyclosporin-A level due to Saint-John's-wort in heart transplant patients. Journal of Heart and Lung Transplantation 20(7):795.
- Alscher DM, Klotz U. 2003. Drug interaction of herbal tea containing St. John's wort with cyclosporine. Transplant International 16(7):543-544.
- Barnes J, Anderson LA, Philipson JD. 2007. Herbal Medicines, 3rd edition. London (GB): The Pharmaceutical Press.
- Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR. 2000. Drug interaction between St. John's wort and cyclosporine. The Annals of Pharmacotherapy 34(9):1013-1016.
- Bauer S, Störmer E, Johne A, Krüger H, Budde K, Neumayer HH, Roots I, Mai I. 2003. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. British Journal of Clinical Pharmacology 55(2):203-211.
- Bolley R, Zülke C, Kammerl M, Fischereder M, Krämer BK. 2002. Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John's wort. Transplantation 73(6):1009.
- Bradley PR, editor. 2006. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications. 2010.
- De Maat MM, Hoetelmans RM, Math t RA, van Gorp EC, Meenhorst PL, Mulder JW, Beijnen JH. 2001. Drug interaction between St John's wort and nevirapine. AIDS 15(3):420-421.
- Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. 2003. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clinical Pharmacology and Therapeutics 73(1):41-50.
- Dürr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K. 2000.
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
- Ernst E. 1999. Second thoughts about the safety of St. John's wort. Lancet 354(9195):20142016.
- Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ. 2004. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clinical Pharmacology and Therapeutics 76(4):323-329.
- Gorski JC, Hamman MA, Wang Z, Vasavada N, Huang S, Hall SD. 2002. The effect of St John's wort on the efficacy of oral contraception. Clinical Pharmacology and Therapeutics 71:P25.
- Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC. 2003. The interaction between St. John's wort and an oral contraceptive. Clinical Pharmacology and Therapeutics 74(6):525-535.
- Hebert MF, Park JM, Chen YL, Akhatar S, Larson AM. 2004. Effects of St. John's wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. Journal of Clinical Pharmacology 44(1):89-94.
- Hoffmann D. 2003. Medical Herbalism: The Science and Practice of Herbal Medicine. Rochester (VT): Healing Arts Press.
- Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. 2004. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. British Journal of Clinical Pharmacology 57(5):592-599.
- Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich, M, Roots I. 1999. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clinical Pharmacology and Therapeutics 66(4):338-345.
- Karliova M, Treichel U, Malagò M, Frilling A, Gerken G, Broelsch CE. 2000. Interaction of Hypericum perforatum (St. John's wort) with cyclosporin A metabolism in a patient after liver transplantation. Journal of Hepatology 33(5):853-855.
- Mai I, Krüger H, Budde K, Johne A, Brockmöller J, Neumayer HH, Roots I. 2000. Hazardous pharmacokinetic interaction of Saint John's wort (Hypericum perforatum) with the immunosuppressant cyclosporin. International Journal of Clinical Pharmacology and Therapeutics 38(10):500-502.
- Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A. 2002. Effects of St John's wort on irinotecan metabolism. Journal of the National Cancer Institute 94(16):1247-1249.
- Maurer A, Johne A, Bauer S, Brockmoller F, Conath I, Roots M, Langheinrich M, Hubner WD. 1999. Interaction of St. John's wort extract with phenprocoumon [Abstract]. European Journal of Clinical Pharmacology 55:A22.
- Mills S, Bone K. 2005. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone.
- Moschella C, Jaber BL. 2001. Interaction between cyclosporine and Hypericum perforatum (St. John's wort) after organ transplantation. American Journal of Kidney Diseases 38(5):1105-1107.
- Mueller SC, Uehleke B, Woehling H, Petzsch M, Majcher-Peszynska J, Hehl EM, Sievers H, Frank B, Riethling AK, Drewelow B. 2004. Effect of St. John's wort dose and preparations on the pharmacokinetics of digoxin. Clinical Pharmacology and Therpeutics 75(6):546-557.
- Murphy A, Kern SE, Stanczyk FZ, Westhoff CL. 2005. Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception 71(6):402-408.
- Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J. 2003. Interaction of St. John's wort with low-dose oral contraceptive therapy: a randomized controlled trial. British Journal of Clinical Pharmacology 56(6):683-690.
- Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. 2000. Indinavir concentrations and St John's wort. Lancet 355(9203):547-548.
- Rey JM, Walter G. 1998. Hypericum perforatum (St John's wort) in depression: pest or blessing? The Medical Journal of Australia 169(11-12):583-586.
- Roby CA, Dryer DA, Burstein AH. 2001. St. John's wort: effect on CYP2D6 activity using dextromethorphan-dextrorphan ratios. Journal of Clinical Psychopharmacology 21(5):530-532.
- Ruschitzka F, Meier PJ, Turina M, Lüscher TF, Noll G. 2000. Acute heart transplant rejection due to Saint John's wort. Lancet 355(9203):548-549.
- Schwarz UI, Büschel B, Kirch W. 2003. Unwanted pregnancy on self- medication with St John's wort despite hormonal contraception. British Journal of Clinical Pharmacology 55(1):112-113.
- Smith P, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ. 2004. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 24(11):1508-1514.
- Sparreboom A, Cox MC, Acharya MR, Figg WD. 2004. Herbal remedies in the United States: potential adverse interactions with anticancer agents. Journal of Clinical Oncology 22(12):2489-2503.
- Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K, Arakawa M, Sakamoto K, Masada M, Miyamori I, Fujimura A. 2001. Different effects of St John's Wort on the pharmacokinetics of simvastatin and pravastatin. Clinical Pharmacology and Therapeutics 70(6):518-524.
- Tannergren C, Engman H, Knutson L, Hedeland M, Bondesson U, Lennernäs H. 2004. St. John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. Clinical Pharmacology and Therapeutics 75(4):298-309.
- Turton-Weeks SM, Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR. 2001. St John's wort: a hidden risk for transplant patients. Progress in Transplantation 11(2):116-120.
- Wang ZQ, Gorski C, Hamman MA, Huang S, Lesko LJ, Hall SD. 2001. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clinical Pharmacology and Therapeutics 70(4):317-326.
- Wichtl M, editor. 2004. Herbal Drugs and Phytopharmaceuticals: A Handbook for Practice on a Scientific Basis, 3rd edition. Stuttgart (D): Medpharm GmbH Scientific Publishers.
1 im Text zitierte Studie hat keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).
Bekannte Nebenwirkungen
When using this product you may experience mild gastrointestinal disturbances, restlessness, and/or headaches (Barnes et al. 2007; ESCOP 2003).
Von Health Canada zitierte Quellen (2)
- Barnes J, Anderson LA, Philipson JD. 2007. Herbal Medicines, 3rd edition. London (GB): The Pharmaceutical Press.
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience muscle rigidity or contractions, tremors, agitation/confusion, increased heart rate, or hypersensitivity/allergy (Boyer 2023; Mayo Clinic Staff 2022; Erner et al. 2003; Papakostas et al. 2007; Barnes et al. 2007; ESCOP 2003).
Von Health Canada zitierte Quellen (6)
- Barnes J, Anderson LA, Philipson JD. 2007. Herbal Medicines, 3rd edition. London (GB): The Pharmaceutical Press.
- Boyer EW. Liebelt EL, Ganetsky M. 2023. Serotonin syndrome (serotonin toxicity). UpToDate. [Accessed 2023 September 11]. Available from: https://www.uptodate.com/contents/serotonin-syndrome-serotonin-toxicity
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
- Erner RA, Meglathery SB, Van Decker WA, Gallagher RM. 2003. Serotonin Syndrome and Other Serotonergic Disorders, Pain Medicine, Volume 4, Issue 1, Pages 63-74.
- Mayo Clinic Staff. 2022. Persistent depressive disorder. Mayo Clinic. [Accessed 2023 September 11]. Available from : https://www.mayoclinic.org/diseases-conditions/persistent-depressive-disorder/diagnosis-treatment/drc-20350935
- Papakostas GI, Crawford CM, Scalia MJ, Fava M. 2007. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. A replication of findings with the use of a double-blind, placebo-controlled trial of Hypericum perforatum versus fluoxetine. Neuropsychobiology 56(2-3):132-137.
1 im Text zitierte Studie hat keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).
Monografie von Health Canada vom 26. Juli 2024
ST. JOHN'S WORT - HYPERICUM PERFORATUM - Topical
Vorsichtsmaßnahmen und Warnhinweise
For external use only.
When using this product avoid contact with eyes. If contact occurs, rinse thoroughly with water.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or last (for) more than 7 days.
Keep out of reach of children. If swallowed, call a poison control centre or get medical help right away.
Gegenanzeigen
Do not use on deep or puncture wounds, animal bites or serious burns.
- Zingiber officinale
Warnhinweis, Geltungsbedingung und zitierte Studien lesen
Offizieller Originaltext auf Englisch.
GINGER - ZINGIBER OFFICINALE
Art der Anwendung: Oral
Vorsichtsmaßnahmen und Warnhinweise
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Sie betreffen die Zutat, nicht dieses Produkt oder seine Dosis. Sie ersetzen keinen ärztlichen Rat.
Liste in der amtlichen Überarbeitung vom (Register: Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise).
Ist eine Angabe zu diesem Produkt falsch oder veraltet, ob Sie Leser oder Marke sind? Schreiben Sie an contact@compoatlas.com: Jede Korrektur wird im Korrekturprotokoll veröffentlicht.